心血管臨床試験の世界市場レポート 2025年

心血管臨床試験市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.0％で75億3,000万米ドルに成長します。予測期間における成長の背景には、高齢化、新興市場、精密医療、デジタルヘルス技術、患者中心の臨床試験への注目などがあります。予測期間における主な動向としては、共同研究の増加、技術の進歩、製品の革新、新製品の開発、配合剤のジェネリック医薬品の発売などが挙げられます。

今後数年間は、製造活動の拡大が延長コードリール市場の拡大を牽引すると予想されます。製造活動には、原材料や部品から様々な変形、組立、仕上げの段階を経て商品を生産するプロセスが含まれます。このような製造活動の増加は、自動化とロボット工学の採用、世界の市場の拡大、先進国と新興国双方の経済成長、研究開発への継続的な投資によってもたらされます。延長コードリールは、効率的で安全かつ信頼性の高い配電ソリューションを提供することで、こうした活動を支える重要な役割を担っており、製造環境における生産性、安全性、業務効率の向上に貢献しています。例えば、2023年2月にカナダ統計局が発表したところによると、カナダの製造業は大幅な成長を遂げ、総売上高は17.9%増加し、2022年には8,509億米ドルに達しました。その結果、製造活動の増加が延長コード・リールの需要に拍車をかけています。

この分野で事業を展開する主要企業は、CRO（医薬品開発業務受託機関）との提携など戦略的提携の構築に注力することで、事業領域を拡大し、より幅広い顧客にサービスを提供しています。CROとの提携は臨床研究分野において最も重要であり、臨床試験や研究の様々な段階において専門的なサービスやサポートを提供します。例えば、スウェーデンに本社を置くバイオ製薬会社Cereno Scientific ABは、最近スウェーデンのフルサービス CROであるClinical Trial Consultants（CTC）とパートナーシップを締結しました。この提携は、動脈および静脈血栓症予防をターゲットとするヒストン脱アセチル化酵素阻害剤CS014の第I相試験を実施することを目的としています。CTCは、スウェーデンにおけるプロトコール開発や臨床試験申請プロセスなど、第I相試験の準備において重要な役割を果たします。2024年前半に開始が予定されているこの第I相試験は、心血管研究の取り組みに大きな進展をもたらすものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界心血管臨床試験PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の心血管臨床試験市場：成長率分析
• 世界の心血管臨床試験市場の実績：規模と成長, 2019-2024
• 世界の心血管臨床試験市場の予測：規模と成長, 2024-2029, 2034F
• 世界心血管臨床試験総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の心血管臨床試験市場フェーズ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• フェーズI
• フェーズII
• フェーズIII
• フェーズIV
• 世界の心血管臨床試験市場研究デザインによる、実績と予測, 2019-2024, 2024-2029F, 2034F
• 介入的
• 観察的
• 拡張アクセス
• 世界の心血管臨床試験市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性冠症候群
• 冠動脈疾患
• 虚血性心疾患
• 肺動脈高血圧
• 脳卒中
• 不整脈
• 心不全
• その他の適応症
• 世界の心血管臨床試験市場、フェーズIのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒトに対する最初の臨床試験
• 用量漸増研究
• 安全性および忍容性試験
• 薬物動態学および薬力学研究
• 世界の心血管臨床試験市場、フェーズIIのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 有効性研究
• 最適な投与量と投与経路の研究
• 初期の安全性と有効性試験
• バイオマーカー開発試験
• 世界の心血管臨床試験市場、フェーズIIIのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 大規模有効性試験
• ランダム化比較試験（RCT）
• 長期安全性および有効性研究
• 多施設試験
• 世界の心血管臨床試験市場、フェーズIVのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 市販後調査
• 長期安全性試験
• リアルワールドエビデンス（RWE）研究
• 比較効果調査

第7章 地域別・国別分析

• 世界の心血管臨床試験市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の心血管臨床試験市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 心血管臨床試験市場：競合情勢
• 心血管臨床試験市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Merck & Co. Inc.
• Baxter International Inc.
• IQVIA Holdings Inc.
• SGS S.A.
• PPD Inc.
• WuXi AppTec Co. Ltd.
• Caidya
• Syneos Health Inc.
• Charles River Laboratories International Inc.
• Sanofi

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 心血管臨床試験市場2029：新たな機会を提供する国
• 心血管臨床試験市場2029：新たな機会を提供するセグメント
• 心血管臨床試験市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cardiovascular clinical trials are investigations aimed at discovering new methods to prevent, diagnose, treat, and manage cardiovascular illnesses (CVDs) such as coronary artery disease, heart failure, arrhythmias, and hypertension. These studies play a crucial role in advancing medical knowledge and enhancing patient care in the field of cardiology. Clinical trials in this domain typically focus on testing new medications, procedures, or devices related to heart health and stroke outcomes.

The main phases of cardiovascular clinical trials include phase I, phase II, phase III, and phase IV. Phase I clinical trials represent the initial stage of testing a new treatment on a small group of people to evaluate its safety and dosage. These trials may encompass various study designs such as interventional, observational, and expanded access, with indications spanning acute coronary syndrome, coronary artery disease, ischemic heart disease, pulmonary arterial hypertension, stroke, cardiac arrhythmias, heart failure, and others.

The cardiovascular clinical trials market research report is one of a series of new reports from The Business Research Company that provides cardiovascular clinical trials market statistics, including the cardiovascular clinical trials industry global market size, regional shares, competitors with cardiovascular clinical trials market share, detailed cardiovascular clinical trials market segments, market trends, and opportunities, and any further data you may need to thrive in the cardiovascular clinical trials industry. These cardiovascular clinical trials market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cardiovascular clinical trials market size has grown strongly in recent years. It will grow from $5.34 billion in 2024 to $5.73 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to increased myocardial infarction, regulatory environment, increased disease burden, advancements in genomics, and increased demand for new drug development.

The cardiovascular clinical trials market size is expected to see strong growth in the next few years. It will grow to $7.53 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to an aging population, emerging markets, precision medicine, digital health technologies, and a focus on patient-centric trials. Major trends in the forecast period include increased collaborations, technological advancements, product innovations, new product developments, and the launch of generic versions of combination drugs.

The growth of manufacturing activities is expected to drive the expansion of the extended cord reels market in the coming years. Manufacturing activities involve the processes of producing goods from raw materials or components through various stages of transformation, assembly, and finishing. This increase in manufacturing activities is driven by the adoption of automation and robotics, global market expansion, economic growth in both developed and developing countries, and ongoing investments in research and development. Extended cord reels play a vital role in supporting these activities by providing efficient, safe, and reliable power distribution solutions, which help enhance productivity, safety, and operational efficiency in manufacturing environments. For example, in February 2023, Statistics Canada reported that the manufacturing industry in Canada saw substantial growth, with total sales rising by 17.9% to reach $850.9 billion in 2022. As a result, the rise in manufacturing activities is fueling the demand for extended cord reels.

Leading companies operating in the cardiovascular clinical trials arena are concentrating on forging strategic alliances, such as partnerships with contract research organizations (CROs), to broaden their reach and serve a wider clientele. Collaborating with CROs holds paramount importance in the clinical research sector, facilitating specialized services and support across various stages of clinical trials and research endeavors. For instance, Cereno Scientific AB, a biopharmaceutical firm based in Sweden, recently entered into a partnership with Clinical Trial Consultants (CTC), a full-service CRO in Sweden. This collaboration aims to conduct a Phase I study for CS014, a histone deacetylase inhibitor targeting arterial and venous thrombosis prevention. CTC will play a pivotal role in Phase I trial preparations, including protocol development and clinical trial application processes in Sweden. Scheduled to commence in the first half of 2024, this Phase I trial marks a significant advancement in cardiovascular research efforts.

In February 2023, AstraZeneca, a pharmaceutical company headquartered in the United States, completed the acquisition of CinCor Pharma for $1.8 billion. This strategic acquisition bolsters AstraZeneca's cardiorenal pipeline by incorporating baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) designed for blood pressure reduction in individuals with treatment-resistant hypertension. CinCor Pharma, a clinical-stage biopharmaceutical company based in the US, specializes in cardiovascular clinical trials and contributes valuable assets to AstraZeneca's portfolio.

Major companies operating in the cardiovascular clinical trials market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Baxter International Inc., IQVIA Holdings Inc., SGS S.A., PPD Inc., WuXi AppTec Co. Ltd., Caidya, Syneos Health Inc., Charles River Laboratories International Inc., Sanofi, ICON plc, Medpace Holdings Inc., Cardiovascular Clinical Sciences., ProRelix Services LLP, Worldwide Clinical Trials

North America was the largest region in the cardiovascular clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiovascular clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cardiovascular clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cardiovascular clinical trials market includes revenues earned by entities by providing services, such as protocol development, regulatory affairs, and patient recruitment and retention. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cardiovascular Clinical Trials Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cardiovascular clinical trials market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cardiovascular clinical trials ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cardiovascular clinical trials market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Phase: Phase I; Phase II; Phase III; Phase IV
• 2) By Study Design: Interventional; Observational; Expanded Access
• 3) By Indication: Acute Coronary Syndrome; Coronary Artery Disease; Ischemic Heart Disease; Pulmonary Arterial Hypertension; Stroke; Cardiac Arrhythmias; Heart Failure; Other Indications
• Subsegments:
• 1) By Phase I: First-in-Human Trials; Dose Escalation Studies; Safety and Tolerability Studies; Pharmacokinetics And Pharmacodynamics Studies
• 2) By Phase II: Efficacy Studies; Optimal Dosage And Administration Route Studies; Early Safety And Efficacy Trials; Biomarker Development Trials
• 3) By Phase III: Large-Scale Efficacy Trials; Randomized Controlled Trials (RCTs); Long-Term Safety And Efficacy Studies; Multicenter Trials
• 4) By Phase IV: Post-Marketing Surveillance; Long-Term Safety Studies; Real-World Evidence (RWE) Studies; Comparative Effectiveness Research
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cardiovascular Clinical Trials Market Characteristics

3. Cardiovascular Clinical Trials Market Trends And Strategies

4. Cardiovascular Clinical Trials Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Cardiovascular Clinical Trials Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cardiovascular Clinical Trials PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cardiovascular Clinical Trials Market Growth Rate Analysis
• 5.4. Global Cardiovascular Clinical Trials Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cardiovascular Clinical Trials Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cardiovascular Clinical Trials Total Addressable Market (TAM)

6. Cardiovascular Clinical Trials Market Segmentation

• 6.1. Global Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phase I
• Phase II
• Phase III
• Phase IV
• 6.2. Global Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interventional
• Observational
• Expanded Access
• 6.3. Global Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Coronary Syndrome
• Coronary Artery Disease
• Ischemic Heart Disease
• Pulmonary Arterial Hypertension
• Stroke
• Cardiac Arrhythmias
• Heart Failure
• Other Indications
• 6.4. Global Cardiovascular Clinical Trials Market, Sub-Segmentation Of Phase I, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First-in-Human Trials
• Dose Escalation Studies
• Safety and Tolerability Studies
• Pharmacokinetics And Pharmacodynamics Studies
• 6.5. Global Cardiovascular Clinical Trials Market, Sub-Segmentation Of Phase II, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Efficacy Studies
• Optimal Dosage And Administration Route Studies
• Early Safety And Efficacy Trials
• Biomarker Development Trials
• 6.6. Global Cardiovascular Clinical Trials Market, Sub-Segmentation Of Phase III, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Large-Scale Efficacy Trials
• Randomized Controlled Trials (RCTs)
• Long-Term Safety And Efficacy Studies
• Multicenter Trials
• 6.7. Global Cardiovascular Clinical Trials Market, Sub-Segmentation Of Phase IV, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Post-Marketing Surveillance
• Long-Term Safety Studies
• Real-World Evidence (RWE) Studies
• Comparative Effectiveness Research

7. Cardiovascular Clinical Trials Market Regional And Country Analysis

• 7.1. Global Cardiovascular Clinical Trials Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cardiovascular Clinical Trials Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cardiovascular Clinical Trials Market

• 8.1. Asia-Pacific Cardiovascular Clinical Trials Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cardiovascular Clinical Trials Market

• 9.1. China Cardiovascular Clinical Trials Market Overview
• 9.2. China Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cardiovascular Clinical Trials Market

• 10.1. India Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cardiovascular Clinical Trials Market

• 11.1. Japan Cardiovascular Clinical Trials Market Overview
• 11.2. Japan Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cardiovascular Clinical Trials Market

• 12.1. Australia Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cardiovascular Clinical Trials Market

• 13.1. Indonesia Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cardiovascular Clinical Trials Market

• 14.1. South Korea Cardiovascular Clinical Trials Market Overview
• 14.2. South Korea Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cardiovascular Clinical Trials Market

• 15.1. Western Europe Cardiovascular Clinical Trials Market Overview
• 15.2. Western Europe Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cardiovascular Clinical Trials Market

• 16.1. UK Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cardiovascular Clinical Trials Market

• 17.1. Germany Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cardiovascular Clinical Trials Market

• 18.1. France Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cardiovascular Clinical Trials Market

• 19.1. Italy Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cardiovascular Clinical Trials Market

• 20.1. Spain Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cardiovascular Clinical Trials Market

• 21.1. Eastern Europe Cardiovascular Clinical Trials Market Overview
• 21.2. Eastern Europe Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cardiovascular Clinical Trials Market

• 22.1. Russia Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cardiovascular Clinical Trials Market

• 23.1. North America Cardiovascular Clinical Trials Market Overview
• 23.2. North America Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cardiovascular Clinical Trials Market

• 24.1. USA Cardiovascular Clinical Trials Market Overview
• 24.2. USA Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cardiovascular Clinical Trials Market

• 25.1. Canada Cardiovascular Clinical Trials Market Overview
• 25.2. Canada Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cardiovascular Clinical Trials Market

• 26.1. South America Cardiovascular Clinical Trials Market Overview
• 26.2. South America Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cardiovascular Clinical Trials Market

• 27.1. Brazil Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cardiovascular Clinical Trials Market

• 28.1. Middle East Cardiovascular Clinical Trials Market Overview
• 28.2. Middle East Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cardiovascular Clinical Trials Market

• 29.1. Africa Cardiovascular Clinical Trials Market Overview
• 29.2. Africa Cardiovascular Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cardiovascular Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cardiovascular Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cardiovascular Clinical Trials Market Competitive Landscape And Company Profiles

• 30.1. Cardiovascular Clinical Trials Market Competitive Landscape
• 30.2. Cardiovascular Clinical Trials Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Cardiovascular Clinical Trials Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Eli Lilly and Company
• 31.3. Gilead Sciences Inc.
• 31.4. Amgen Inc.
• 31.5. Boehringer Ingelheim International GmbH
• 31.6. Merck & Co. Inc.
• 31.7. Baxter International Inc.
• 31.8. IQVIA Holdings Inc.
• 31.9. SGS S.A.
• 31.10. PPD Inc.
• 31.11. WuXi AppTec Co. Ltd.
• 31.12. Caidya
• 31.13. Syneos Health Inc.
• 31.14. Charles River Laboratories International Inc.
• 31.15. Sanofi

32. Global Cardiovascular Clinical Trials Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cardiovascular Clinical Trials Market

34. Recent Developments In The Cardiovascular Clinical Trials Market

35. Cardiovascular Clinical Trials Market High Potential Countries, Segments and Strategies

• 35.1 Cardiovascular Clinical Trials Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cardiovascular Clinical Trials Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cardiovascular Clinical Trials Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer